At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LUCD LUCID DIAGNOSTICS INC.
Pre-Market Trading 11-22 08:56:13 EST
0.9990
-0.0010
-0.10%
盘前0.9990
+0.00000.00%
08:25 EST
High1.02
Low0.9800
Vol315.74K
Open1.00
D1 Closing1.00
Amplitude4.00%
Mkt Cap59.28M
Tradable Cap24.26M
Total Shares59.34M
T/O315.45K
T/O Rate1.30%
Tradable Shares24.28M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Lucid Diagnostics submits clinical evidence for EsoGuard Esophagea DNA test
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.